CHLORPROMAZINE vs piperacetazine: Leaving the study early
- Population
- patients with schizophrenia
- Intervention
- CHLORPROMAZINE
- Comparison
- piperacetazine
- Outcome
- Leaving the study early
It is very uncertain whether chlorpromazine changes leaving the study early ‐ for any reason compared with piperacetazine (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Chlorpromazine vs piperacetazine Leaving the study early ‐ for any reason · people with schizophrenia It is very uncertain whether chlorpromazine changes leaving the study early ‐ for any reason compared with piperacetazine (very low certainty). Chlorpromazine versus piperacetazine for schizophrenia (2018) · Cochrane Headline outcomes only | RR 0.5 [0.1, 2.56] | 4 studies · 256 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Chlorpromazine versus piperacetazine for schizophrenia 2018 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- CHLORPROMAZINE vs Clotiapine · patients with schizophrenia · 1 review
- CHLORPROMAZINE vs haloperidol · patients with psychosis‐induced aggression or agitation · 1 review
- CHLORPROMAZINE vs placebo · patients with schizophrenia · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.